Omid Farokhzad Biography and Net Worth

Chair & Chief Executive Officer of Seer

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 190 papers and is an inventor of over 250 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB; merged with Cartesian Therapeutics NASDAQ: RNAC), Tarveda Therapeutics and PrognomiQ, where he serves as Chair of Board. Omid is a 2023 Mustafa Prize and the 2013 RUSNANOPRIZE for his work on nanomaterial surface modificagtion. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.

What is Omid Farokhzad's net worth?: The estimated net worth of Omid Farokhzad is at least $2.46 million as of November 19th, 2025. Mr. Farokhzad owns 1,238,230 shares of Seer stock worth more than $2,464,078 as of August 28th. This net worth evaluation does not reflect any other assets that Mr. Farokhzad may own. Learn More about Omid Farokhzad's net worth.
How do I contact Omid Farokhzad?: The corporate mailing address for Mr. Farokhzad and other Seer executives is , , . Seer can also be reached via phone at 650-453-0000 and via email at [email protected]. Learn More on Omid Farokhzad's contact information.
Has Omid Farokhzad been buying or selling shares of Seer?: Omid Farokhzad has not been actively trading shares of Seer during the last ninety days. Most recently, Omid Farokhzad sold 33,838 shares of the business's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $1.97, for a transaction totalling $66,660.86. Following the completion of the sale, the chief executive officer now directly owns 1,238,230 shares of the company's stock, valued at $2,439,313.10. Learn More on Omid Farokhzad's trading history.
Who are Seer's active insiders?: Seer's insider roster includes Omid Farokhzad (), Omid Farokhzad (Chair & Chief Executive Officer), David Horn (CFO), and Omead Ostadan (COO). Learn More on Seer's active insiders.
Are insiders buying or selling shares of Seer?: During the last twelve months, insiders at the sold shares 5 times. They sold a total of 65,907 shares worth more than $130,469.09. The most recent insider tranaction occured on August, 18th when CFO David R Horn sold 7,309 shares worth more than $14,837.27. Insiders at Seer own 11.3% of the company. Learn More about insider trades at Seer.
Information on this page was last updated on 8/18/2026.

Omid Farokhzad Insider Trading History at Seer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2025	Sell	33,838	$1.97	$66,660.86	1,238,230
8/20/2025	Sell	33,992	$2.04	$69,343.68	1,272,068
2/4/2025	Sell	8,068	$2.24	$18,072.32	1,428,217
3/7/2024	Sell	52,857	$2.03	$107,299.71	1,436,285
8/23/2023	Buy	40,000	$2.45	$98,000.00	807,744
2/21/2023	Sell	13,840	$4.13	$57,159.20	767,744
2/7/2023	Sell	8,379	$4.67	$39,129.93	379,584
1/17/2023	Sell	4,800	$5.12	$24,576.00	399,123
2/17/2021	Sell	354,741	$64.15	$22,756,635.15	384,487
2/1/2021	Sell	313,369	$64.15	$20,102,621.35	610,856
12/8/2020	Sell	526,315	$19.00	$9,999,985.00	279,223

Omid Farokhzad Buying and Selling Activity at Seer

Seer Company Overview

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Today's Range

Now: $2.00

$1.98

$2.02

50 Day Range

MA: $2.02

$1.62

$2.24

2 Week Range

Now: $2.00

$1.55

$2.41

Volume

155,117 shs

Average Volume

611,410 shs

Market Capitalization

$110.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56